May 30, 2014
The European Commission approved Takeda Pharmaceutical’s ulcerative colitis (UC) and Crohn’s disease (CD) treatment Entyvio (vedolizumab) on May 27. According to Takeda, Entyvio will be indicated for adults with mild to severe active UC or mild to severe active CD...read more